Floatz logo

FAPi-46

Interstitial Lung Disease

University of California, Los AngelesSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Interstitial Lung Disease cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
National Institute for Tuberculosis and Lung Diseases, Poland
Phase 4BB
TREPROSTINIL PHOSPHATE
United Therapeutics
Phase 3BB
Cyclophosphamide
Intergroupe Francophone de Cancerologie Thoracique
Phase 2/3B
Sildenafil
University of California, Los Angeles
Phase 4B
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Royal Brompton & Harefield NHS Foundation Trust
Phase 2/3B

View all 35 →

Same molecule, other indications

FAPi-46 is also rated in:

cholangiocarcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
melanomaDormant
CCC
Indicative ·
53 / 100
View asset →
amyloidosisDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →